HIV market stalwart Gilead Sciences Inc. is once again positioned for huge success with its recently launched single-tablet regimen Biktarvy (BIC/F/TAF), but competitor ViiV Healthcare still could emerge as the market leader over the next decade, Datamonitor Healthcare analysts conclude.
The US FDA approved Gilead's Biktarvy, which combines the integrase inhibitor bictegravir, the nucleoside reverse transcriptase inhibitorEmtriva (emtricitabine) and...






